Table 5.
Time-integrated biomarker concentrations and MBDA scores in the groups with persistent disease activity, intermittent remission and sustained remission over 12 months
| PDA (n = 14) | DAS28-IR (n = 62) | DAS28-SR (n = 69) | p value | SDAI-IR (n = 67) | SDAI-SR (n = 29) | p value | ACR/EULAR Boolean-IR (n = 52) | ACR/EULAR Boolean-SR (n = 14) | p value | |
|---|---|---|---|---|---|---|---|---|---|---|
| tiEGF (pg/ml) | 208 (202, 368) | 276 (175, 358) | 257 (149, 359) | ns | 275 (161, 358) | 286 (146, 329) | ns | 243 (161, 324) | 275.71 (117.88, 328.72) | ns |
| tiIL-6 (pg/ml) | 15.82 (13.07, 38.96) | 12.66 (7.46, 17.85) | 8.06 (5.88, 11.09) | < 0.0001 | 8.77 (6.72, 14) | 7.89 (5.13, 11.06) | 0.0009 | 8.37 (6.19, 11.96) | 8.23 (5.88, 10.18) | 0.0013 |
| tiLeptin (ng/ml) | 18.89 (97.78, 33.32) | 16.99 (6.28, 35.78) | 7.12 (3.82, 14.39) | 0.0005 | 11.82 (4.91, 26.01) | 6.38 (3.82, 9.99) | 0.0038 | 8.04 (4.75, 23.76) | 6.80 (3.32, 10.24) | 0.015 |
| tiMMP-1(ng/ml) | 6.13(4.26, 8.86) | 7.23 (4.92, 9.30) | 6.87 (4.45, 9.93) | ns | 7.23 (4.92, 9.89) | 6.51 (4.52, 9.93) | ns | 6.69 (4.95, 9.61) | 7.67 (5.00, 9.41) | ns |
| tiMMP-3 (ng/ml) | 28.99 (13.81, 39.76) | 23.02 (17.38, 33.75) | 27.29 (20.97, 36.47) | ns | 27.55 (19.50, 38.74) | 22.22 (15.46, 33.18) | ns | 25.99 (17.42, 33.96) | 22.36 (15.46, 34.76) | ns |
| tiResistin (ng/ml) | 11.66 (80.60, 13.07) | 7.57 (6.15, 9.50) | 7.56 (6.61, 9.17) | ns | 7.52 (6.29, 8.75) | 8.42 (6.56, 9.88) | ns | 7.47 (6.41, 9.20) | 8.61 (6.63, 10.15) | ns |
| tiSAA (ug/ml) | 3.99 (3.20, 8.47) | 2.01 (1.00, 4.43) | 1.29 (0.99, 4.44) | 0.0001 | 1.84 (0.93, 3.10) | 1.06 (0.74, 2.16) | 0.0002 | 1.71 (0.90, 2.59) | 0.94 (0.75, 2.28) | 0.0004 |
| tiTNFR1 (ng/ml) | 1.79 (1.47, 2.10) | 1.56 (1.37, 2.02) | 1.56 (1.37, 1.97) | ns | 1.53 (1.35, 1.97) | 1.51 (1.36, 1.82) | ns | 1.58 (1.37, 1.98) | 1.70 (1.28, 2.00) | ns |
| tiVCAM1 (ng/ml) | 590 (476, 652) | 527 (427, 618) | 490 (437, 571) | ns | 493 (433, 578) | 486 (429, 613) | ns | 495 (441, 594) | 479 (397, 636) | ns |
| tiVEGF (pg/ml) | 338 (267, 487) | 262 (198, 370) | 264 (182, 409) | 0.042 | 240 (182, 381) | 226 (154, 423) | ns | 212 (163, 378) | 213 (154, 297) | 0.042 |
| tiYKL40 (ng/ml) | 79.23 (60.80, 143.49) | 60.56 (40.67, 102.18) | 54.90 (34.77, 99.67) | ns | 54.96 (35,25, 82.49) | 48.78 (34.62, 120.90) | ns | 53.50 (33.45, 100) | 59.06 (41.76, 118.82) | ns |
| tiCRP (mg/ml) | 8.38 (4.25, 12.70) | 3.52 (1.64, 7.75) | 1.73 (6.53, 3.47) | < 0.0001 | 1.98 (1.05, 1.35) | 0.98 (0.65, 3.31) | 0.0001 | 2.09 (0.9, 3.75) | 0.93 (0.52, 2.70) | < 0.0001 |
| tiMBDA score (0–100) | 43 (36, 51) | 33 (22, 41) | 24 (17, 33) | < 0.0001 | 28 (20, 34) | 22 (16, 33) | < 0.0001 | 25 (20, 34) | 22 (15, 33) | < 0.0001 |
Comparison of time-integrated (ti) values in the persistent disease activity (PDA, i.e. no remission by any criteria at any visit) group, the intermittent remission (IR) and the sustained remission (SR) group, based on DAS28-ESR, SDAI and ACR/EULAR Boolean definitions of remission. Values are medians (IQR). Values across the PDA/IR/SR groups were assessed using Jonckheere-Terpstra trend test